The capital is pricing the TAME trial as a regulatory gate: once FDA accepts aging as an approvable indication, APAC markets follow. The clinical ledger is a Phase 3 trial, 3,000 participants, composite primary endpoint (cardiovascular disease incidence, cancer, dementia, disability), primary completion 2027, funded by the American Federation for Aging Research, enrolling a metformin-naive cohort aged 65 to 79. Nir Barzilai at Albert Einstein College of Medicine built the trial structure. FDA accepted that structure in 2023. The drug is generic. The indication, if approved, attaches to metformin -- not to the fund's biotech position.

NMPA's Center for Drug Evaluation does not read FDA indication precedent as normative, and it has no existing regulatory category for aging as a therapeutic target. Its 2024 draft guidance on innovative drug development for chronic disease names glycaemic control, cardiovascular events, and renal endpoints as approvable outcomes; composite aging measures are absent. Singapore's Health Sciences Authority follows TGA's Advisory Committee on Medicines more closely than FDA in metabolic indications. TGA has not opened an aging-disease pathway. Japan's PMDA, under the Act on the Safety of Regenerative Medicine, covers cell therapies and gene therapies in adjacent contexts but publishes no anti-aging drug evaluation criteria. APAC longevity capital allocated on a regulatory-cascade thesis is pricing four agency decisions that have not been made. TAME's primary completion is scheduled for 2027; NMPA's Center for Drug Evaluation has issued no public signal on whether a US aging-indication approval would trigger a parallel guidance review.